Efficacy and safety of target combined chemotherapy in advanced gastric cancer: a meta-analysis and system review

Zou, Kun; Yang, Shuailong; Zheng, Liang; Yang, Chaogang; Xiong, Bin

doi:10.1186/s12885-016-2772-5

Table 1 Basic characteristics of the studies included in this meta-analysis

From: Efficacy and safety of target combined chemotherapy in advanced gastric cancer: a meta-analysis and system review

Study	Regimen	PN	Area	TP	TG	Patient
Bang Y. J 2010 [7]	Trastuzumab + fluoropyrimidine + cisplatin	294	worldwide	FL	EGFR	Selected
Bang Y. J 2010 [7]	fluoropyrimidine-cisplatin	290	worldwide	FL	EGFR	Selected
Wilke H 2014 [8]	Ramucirumab + paclitaxel	330	Asia	SL	VEGFR	Unselected
Wilke H 2014 [8]	Placebo + paclitaxel	335	Asia	SL	VEGFR	Unselected
Shen L 2015 [9]	Bevacizumab + Cisplatin + Capecitabine	100	Asia	FL	VEGFR	Unselected
Shen L 2015 [9]	Placebo + Cisplatin + Capecitabine	102	Asia	FL	VEGFR	Unselected
Lordick F 2013 [10]	Cetuximab + Capecitabine + cisplatin	455	worldwide	FL	EGFR	Unselected
Lordick F 2013 [10]	Capecitabine + cisplatin	449	worldwide	FL	EGFR	Unselected
Waddell T 2013 [12]	Panitumumab + mEOC	278	Europe	FL	EGFR	Unselected
Waddell T 2013 [12]	Epirubicin + Capecitabine + oxaliplatin	275	Europe	FL	EGFR	Unselected
Rao S 2010 [13]	matuzumab + Epirubicin + Capecitabine + cisplatin	35	Europe	FL	EGFR	Selected
Rao S 2010 [13]	Epirubicin + Capecitabine + cisplatin	36	Europe	FL	EGFR	Selected
NCT01246960 [15]	Ramucirumab + Oxaliplatin + Leucovorin + 5-Fu	84	N	FL	VEGFR	Unselected
NCT01246960 [15]	Placebo + Oxaliplatin + Leucovorin + 5-Fu	84	N	FL	VEGFR	Unselected
Ohtsu A 2011 [16]	Bevacizumab + fluoropyrimidine + cisplatin	387	worldwide	FL	VEGFR	Unselected
Ohtsu A 2011 [16]	Placebo + fluoropyrimidine-cisplatin	387	worldwide	FL	VEGFR	Unselected
Du F 2015 [17]	Nimotuzumab + S-1 + Cisplatin	31	Asia	FL	EGFR	Unselected
Du F 2015 [17]	S-1 + Cisplatin	31	Asia	FL	EGFR	Unselected
Koizumi W 2013 [18]	TSU-68 + S-1 + cisplatin	45	Asia	FL	VEGFR	Unselected
Koizumi W 2013 [18]	S-1 + cisplatin	46	Asia	FL	VEGFR	Unselected
Satoh T 2015 [19]	Nimotuzumab + irinotecan	40	Asia	SL	EGFR	Unselected
Satoh T 2015 [19]	Irinotecan	42	Asia	SL	EGFR	Unselected
Satoh T 2014 [20]	lapatinib + paclitaxel	132	Asia	SL	EGFR	Selected
Satoh T 2014 [20]	Paclitaxe	129	Asia	SL	EGFR	Selected
Yi J. H 2012 [21]	Sunitinib + docetaxel	56	Asia	SL	VEGFR	Unselected
Yi J. H 2012 [21]	Docetaxel	49	Asia	SL	VEGFR	Unselected
Hecht J. R 2016 [22]	Lapatinib + Capecitabine + Oxaliplatin	272	worldwide	FL	EGFR	Selected
Hecht J. R 2016 [22]	Placebo + Capecitabine + Oxaliplatin	273	worldwide	FL	EGFR	Selected

PN patient number, TP treatment plan, TG the targeted gene, FL first-line, SL second-line, Selected the EGFR-positive, unselected the whole patients, N unknown

Back to article page